News | August 11, 2021
Sequent Scientific net profit at Rs 87.30 lakh in Q1FY22
Formulation business grew by 15 per cent in the quarter
Formulation business grew by 15 per cent in the quarter
Deal signed with AOP Orphan for US commercial rights
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
Subscribe To Our Newsletter & Stay Updated
